Compounds > buparvaquone

Page last updated: 2024-08-25

buparvaquone and Black Fever

buparvaquone has been researched along with Black Fever in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (14.29)	18.2507
2000's	3 (42.86)	29.6817
2010's	2 (28.57)	24.3611
2020's	1 (14.29)	2.80

Authors

Authors	Studies
Croft, SL; Garnier, T; Järvinen, T; Koskinen, A; Mäntylä, A; Nevalainen, T; Rautio, J; Vepsälainen, J	1
Lehto, VP; Mondal, S; Näkki, S; Närvänen, A; Nissinen, T; Rantanen, J; Riikonen, J; Thapa, R	1
Bolás-Fernández, F; Dea-Ayuela, MA; Lalatsa, A; Mauger, M; Serrano, DR; Smith, L	1
Colombo, FA; Pereira-Chioccola, VL; Reimão, JQ; Tempone, AG	1
Croft, SL; Garnier, T; Järvinen, T; Juvonen, R; Kendrick, H; Mäntylä, A; Nevalainen, T; Rautio, J; Vepsälainen, J	1
Brown, M; Croft, S; Garnier, T; Järvinen, T; Lawrence, J; Mäntylä, A	1
Croft, SL; Furtado Campos, JH; Miles, MA; Vexenat, JA	1

Other Studies

7 other study(ies) available for buparvaquone and Black Fever

Article	Year
Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone. Journal of medicinal chemistry, 2004, Jan-01, Volume: 47, Issue:1 Topics: Administration, Oral; Administration, Topical; Alkaline Phosphatase; Animals; Antiprotozoal Agents; Cricetinae; Female; Humans; Hydrolysis; In Vitro Techniques; Leishmania; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Macrophages, Peritoneal; Mice; Naphthoquinones; Organophosphates; Permeability; Prodrugs; Skin; Solubility; Water	2004
Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis. PLoS neglected tropical diseases, 2021, Volume: 15, Issue:6 Topics: Animals; Antiprotozoal Agents; Drug Carriers; Female; Hordeum; Injections, Intraperitoneal; Leishmania donovani; Leishmaniasis, Visceral; Macrophages; Mice, Inbred BALB C; Nanoparticles; Naphthoquinones; Silicon	2021
Orally Bioavailable and Effective Buparvaquone Lipid-Based Nanomedicines for Visceral Leishmaniasis. Molecular pharmaceutics, 2018, 07-02, Volume: 15, Issue:7 Topics: Administration, Oral; Animals; Antiprotozoal Agents; Biological Availability; Cell Line; Disease Models, Animal; Drug Carriers; Drug Compounding; Drug Liberation; Drug Stability; Emulsions; Excipients; Feasibility Studies; Humans; Leishmania infantum; Leishmaniasis, Visceral; Lipids; Male; Mice; Mice, Inbred BALB C; Nanoparticles; Naphthoquinones; Solubility; Treatment Outcome	2018
Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi. Experimental parasitology, 2012, Volume: 130, Issue:3 Topics: Animals; Antiprotozoal Agents; Cell Line; Cells, Cultured; Cricetinae; Disease Models, Animal; Humans; Inhibitory Concentration 50; Leishmania infantum; Leishmaniasis, Visceral; Liposomes; Macaca mulatta; Macrophages, Peritoneal; Male; Mesocricetus; Mice; Mice, Inbred BALB C; Naphthoquinones; Phosphatidylserines	2012
Synthesis and antileishmanial activity of novel buparvaquone oxime derivatives. Bioorganic & medicinal chemistry, 2004, Jul-01, Volume: 12, Issue:13 Topics: Animals; Antiprotozoal Agents; Leishmania donovani; Leishmaniasis, Visceral; Macrophages; Magnetic Resonance Spectroscopy; Microsomes, Liver; Molecular Structure; Naphthoquinones; Oximes; Rats; Rats, Wistar	2004
In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. The Journal of antimicrobial chemotherapy, 2007, Volume: 60, Issue:4 Topics: Animals; Antiprotozoal Agents; Chemistry, Pharmaceutical; Female; Leishmania donovani; Leishmania major; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Liver; Mice; Mice, Inbred BALB C; Naphthoquinones; Prodrugs; Skin	2007
Failure of buparvaquone (Butalex) in the treatment of canine visceral leishmaniosis. Veterinary parasitology, 1998, Volume: 77, Issue:1 Topics: Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Injections, Intramuscular; Leishmaniasis, Visceral; Male; Naphthoquinones	1998